Deadline Extended to May 24, 2018
M2Gen is pleased to announce the launch of the ORIEN NOVA Awards. In support of the ORIEN Mission, these awards encourage ORIEN data sharing and fund ORIEN member research through collaborative learning and team science.
ORIEN member cancer centers are true partners in data exchange and collaboration through the use of a common protocol, Total Cancer Care®.
M2Gen analyzes data from all participating ORIEN centers to more quickly connect patients with clinical trials based on their molecular profile. ORIEN provides the information and tools needed to study the long-term effects of disease, while assisting cancer center member institutions in their development of precision medicine.
Researchers at ORIEN member institutions access the consortium’s large, shared data warehouse to ask new research questions, develop more effective, competitive, grant submissions and participate in cross-institutional collaborations and biomarker discovery projects with academic partners and pharmaceutical companies. This rapid-learning environment allows scientists to analyze and share findings so that that research can be retested and learnings reapplied.
Located in Tampa, Moffitt Cancer Center is the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida, a distinction that recognizes excellence in research, its contributions to clinical trials, prevention and cancer control. Moffitt has made a lasting commitment to the prevention and cure of cancer, working tirelessly in the areas of patient care, research and education to advance one step further in fighting this disease. Moffitt is one of the top-ranked cancer hospitals in the nation and has been listed in U.S. News & World Report as one of the “Best Hospitals” for cancer since 1999. Moffitt treats patients from every county in Florida, every state in the United States and 100+ countries. With more than 4,500 employees, Moffitt has an economic impact on the state of nearly $1.6 billion.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
The Ohio State University Comprehensive Cancer Center– Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) has more than 300 cancer researchers and sub-specialized cancer physicians spanning 12 of the 15 colleges at Ohio State and is one of only four centers funded by the NCI to conduct both phase I and phase II clinical trials on novel anticancer drugs. Treating more than 10,000 patients annually, the center manages hundreds of cancer clinical trials, and holds three prestigious NCI SPORE grants for the study of leukemia, thyroid cancer and sarcoma. In December 2014, The OSUCCC – James opened a transformational 21 floor, 1.1 million square foot, 306-bed cancer hospital that places cancer care operations in close proximity to the institution’s robust research facilities. Working together, clinicians and researchers at the OSUCCC – James are speeding the development and delivery of treatments that target the molecules and markers fueling each person’s unique cancer.
City of Hope is a comprehensive cancer center and independent biomedical research
institution committed to curing cancer, diabetes and other life-threatening
diseases. Designated as a Comprehensive Cancer Center, the highest recognition
bestowed by the National Cancer Institute, City of Hope is also a founding
member of the National Comprehensive Cancer Network and maintains research
and treatment protocols that advance care throughout the nation.
Each year, we treat more than 7,500 new patients, including almost 2,000 who came to City of Hope for a second opinion and transferred their care to us. We conduct more than 300 clinical trials, enrolling more than 5,000 patients, including almost 600 enrolled in interventional trials. City of Hope is one of the few institutions with a genomic tumor board. Our institution also participates in the IBM Watson initiative and has joined the NCI-MATCH clinical trial. Founded more than 100 years ago, City of Hope has one of the nation’s largest and most successful stem cell transplantation programs, with outcomes that are unparalleled. Our physicians are experts in robotic-assisted urologic surgeries and also use this surgical technology to battle lung cancer, liver cancer and other life-threatening illnesses. City of Hope is consistently ranked as one of the nation’s top cancer hospitals by U.S. News & World Report.
UVA Cancer Center’s mission is to reduce the burden of cancer through care for the patients of today, and through research and education for the patients of tomorrow. Approximately 180 cancer researchers are organized around five programs and have more than $50 million in funded research annually. Clinical programs are led by physicians honored as Best Doctors in America® and Newsweek’s Top Cancer Doctors. Our cancer center is one of the first in the country to formalize a pancreatic cancer program with a high-risk clinic. We have the region’s only high-risk breast and ovarian cancer program. UVA established one of the first tumor registries in the world. UVA has been funded since 2001 for the Mid-Atlantic Division of the Cooperative Human Tissue Network. Our researchers and clinicians work diligently to understand why cancer occurs, find innovative ways to treat it and offer the most advanced cancer services in Virginia.
The University of Colorado Cancer Center (CU Cancer Center), located at the University of Colorado Anschutz Medical Campus, is Colorado’s only National Cancer Institute-designated comprehensive cancer center, a distinction recognizing its outstanding contributions to research, clinical trials, prevention and cancer control. CU Cancer Center is a consortium of approximately 400 researchers and physicians at three state universities (University of Colorado Anschutz Medical Campus, University of Colorado Boulder and Colorado State University) and three clinical institutions (University of Colorado Hospital, Children’s Hospital Colorado and Denver VA Hospital) all working toward one goal: translating science into life.
The University of New Mexico Comprehensive Cancer Center (UNM CCC) assures that all New Mexicans have access to world class cancer care and benefit from advances in clinical, transitional and basic cancer research. Our multidisciplinary teams of 116 physicians in every cancer specialty — New Mexico’s largest cancer team — work with our nurses, pharmacists and other cancer professionals to develop a specialized treatment plan for each of our 10,000 patients every year. We provide access to more than 160 cancer clinical trials through the New Mexico Cancer Care Alliance, an “exemplary national model for cancer health care delivery.” In collaboration with our scientific partners (Los Alamos and Sandia National Laboratories, Lovelace Respiratory Research Institute), our 132 scientists are supported by more than $72 million annually in research funds to develop innovative interventions that include education, prevention, novel therapies and precision medicine.
The Morehouse School of Medicine (MSM) Cancer Care & Research Community (CCRC) is made up of special people — students, scientists, clinicians, volunteers, and donors — dedicated to giving their energy, talents and unique skills to provide the best care for our patients and to discover new ways to combat this deadly disease. Our mission is to conduct laboratory, clinical, community-based participatory, and epidemiological cancer research and to better understand and reduce cancer health disparities. Our team does this by working to increase the number of highly competent cancer researchers and clinicians at our facilities, promote cancer screenings and healthy lifestyles, and expand minority participation in clinical oncology trials. CCRC has more than 50 affiliated members engaged in Cancer Immuno-biology, Drug Discovery, Clinical, Implementation Science, and Cancer Health Disparities Research.
As New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey is dedicated to improving the prevention, detection, treatment, and care of patients with cancer, through the transformation of laboratory discoveries into clinical practice and precision care. Rutgers Cancer Institute delivers advanced comprehensive care to adults and children, including access to clinical trials, and conducts cutting-edge cancer research. The leadership of Rutgers Cancer Institute comprises distinguished researchers and physicians who are internationally recognized in their field. Our basic scientists, clinical researchers, and population scientists meet regularly to exchange information to ensure: that laboratory discoveries are refined and applied to clinical care as quickly as possible; that clinical observations reach laboratory researchers on a continuing basis; and that prevention strategies are interwoven in to all research programs.
USC Norris Comprehensive Cancer Center has been leading the fight to make cancer a disease of the past. As one of the original NCI-designated comprehensive cancer centers in the United States, its mission is to treat and prevent cancer by advancing and integrating education, research, and personalized patient care. For more than 40 years, USC Norris has been revolutionizing cancer research with innovative surgical techniques and novel cancer treatments and is listed as one of the nation’s best cancer hospitals in U.S. News & World Report. Discoveries and breakthroughs in cancer biology have led the way to entirely new classes of cancer treatment. USC Norris is at the cutting edge of prevention, detection, and treatment. With a multidisciplinary team of more than 250 dedicated scientists and physicians, USC Norris Comprehensive Cancer Center offers hope for patients with cancer and their families’ cancer.
The John P. Murtha Cancer Center is the military health care system's center of excellence for cancer research and care. Murtha Cancer Center is a core translational research center of the Uniformed Services University of the Health Sciences and has its main clinical site at Walter Reed National Military Medical Center, and partners with the Henry M. Jackson Foundation for the Advancement of Military Medicine to carry out its mission. Murtha Cancer Center serves the cancer needs of 1.2 million active duty service members and 9.1 million health care beneficiaries around the globe. Murtha Cancer Center's main mission is to focus on the readiness needs of the active duty military from the standpoint of cancer prevention, screening, treatment, and rehabilitation back into active duty status. Our research focuses on cancers of particular interest and threat to the active duty population and its younger and diverse demographics. Murtha Cancer Center has additional clinical research sites at several other military medical hospitals, and provides all varieties of complex cancer care as well as clinical trials and research opportunities for our patients. Murtha Cancer Center provides expertise to policymakers in the military health system to inform screening and cancer treatment recommendations across our network. Murtha Cancer Center partners with other governmental, academic, and industry leaders to provide the fullest spectrum of cancer research and care to our active duty, beneficiaries, and veterans.
The Huntsman Cancer Institute mission is to understand cancer from its beginnings,
to use that knowledge in the creation and improvement of cancer treatments,
to relieve the suffering of cancer patients, and to provide education about
cancer risk, prevention, and care.
Huntsman Cancer Institute is a world leader in the study of cancer genetics and manages the Utah Population Database, the largest genetic database in the world, with more than 16 million records linked to genealogies, health records, and vital statistics. Our researchers discovered genes responsible for breast and ovarian cancer(BRCA1 and BRCA2), colon cancer (APC), head and neck cancers (SDH5), and melanoma (p16). We continually develop new approaches to help patients live longer and better lives. With an average of 200 clinical trials open for enrollment at a given time, Huntsman Cancer Institute offers the latest in cancer treatment to patients, some of whom may have few remaining options. Since 1998, we have provided cancer education and outreach to residents of all 50 states and all continents (except Antarctica), with a particular emphasis on underserved Native Americans in our region.
Located at the University of Utah in Salt Lake City, Huntsman Cancer Institute is the only National Cancer Institute-Designated Comprehensive Cancer Center in the Intermountain West, serving the largest geographic area in the country.
Norris Cotton Cancer Center combines advanced cancer research at the Geisel School of Medicine at Dartmouth with patient-centered cancer care at Dartmouth-Hitchcock Medical Center in Lebanon, N.H., and at locations throughout New Hampshire and Vermont. It is one of 45 institutions nationwide that hold the National Cancer Institute’s Comprehensive Cancer Center designation, and the only one located in northern New England.
Located in Atlanta, Winship Cancer Institute of Emory University is Georgia’s first and only National Cancer Institute-designated cancer center. For 79 years, Winship has coordinated and directed cancer research, education, and care throughout Emory University and its health care system, Emory Healthcare. Winship is ranked first in Georgia for cancer care and is one of the top 25 cancer programs in the nation according to U.S. News & World Report. More than 15,000 newly diagnosed cancer patients are seen annually by Winship physicians either within Emory Healthcare or within three other Emory-aligned health care systems in Atlanta. Each of Winship’s 355 faculty members has a faculty appointment in one of 36 departments within Emory University or in other affiliated institutions. With 250 active clinical trials, Winship researchers are dedicated to taking new cancer treatments from the laboratory to patients, providing cancer patients and their families with innovative options in cancer care.
Oklahoma’s only comprehensive academic cancer center, the Stephenson Cancer Center at the University of Oklahoma is a nationally recognized leader in research and patient care. The Stephenson Cancer Center annually ranks among the top cancer centers in the nation for number of patients participating in National Cancer Institute (NCI)-sponsored treatment trials, and it is one of 30 designated lead academic sites in the NCI’s National Clinical Trials Network.
The Stephenson Cancer Center is decreasing the burden of cancer in Oklahoma and nationally by supporting innovative laboratory, clinical and populations-based research. Its 250 research members are conducting more than 200 funded cancer research projects at institutions across Oklahoma, supported by nearly $50 million in annual funding from local and national sponsors. To provide patients with the highest standard of care and ensure the best possible outcomes, the cancer center supports 10 multidisciplinary clinical programs that bring together physician specialists from medical, surgical, and radiation oncology as well as supportive care and clinical research staff.
The University of Iowa Holden Comprehensive Cancer Center is an NCI dedicated comprehensive cancer center dedicated to bringing world class research and cancer care to Iowa, the Midwest and beyond. Located in Iowa City, Holden is a matrix center than spans the university coordinating all cancer-related research, education and patient care by faculty from 41 departments and six colleges, as well as UI Hospitals and Clinics and UI Stead Family Children’s Hospital. Holden offers more than 300 active cancer clinical trials and holds two NCI SPORE grants for the study of lymphoma and neuroendocrine cancers. University of Iowa Hospitals and Clinics has appeared in U.S. News & World Report as one of the “Best Hospitals in America” since it began in 1990 with cancer care ranked among the best repeatedly in a number of specialties.
Roswell Park Comprehensive Cancer Center, based in Buffalo, NY, has led the battle against cancer for over a century with the combined strength of its basic and translational research, multidisciplinary oncology teams, robust cancer prevention and population sciences investigations, educational programs and compassionate team. Founded in 1898, Roswell Park is the only New York state facility outside of New York City to hold the National Cancer Institute designation of comprehensive cancer center, and has been credited with establishing the model for today’s multidisciplinary approach to cancer care. As a founding member of the National Comprehensive Cancer Network, Roswell Park helps set international standards in cancer care. A seamless interface of scientific inquiry and clinical application — evidenced by an aggressive clinical trials program that includes one of the first clinical research centers in the nation to focus specifically on the development of new cancer treatments — affords patients access to promising breakthroughs in cancer diagnostics, technologies and therapies. Through its innovative research in areas like genetics/genomics, cell biology and immunotherapy, Roswell Park is driving the development of new, personalized treatments to improve cancer care both now and for future generations. Learn more at RoswellPark.org.
The University of Kentucky Markey Cancer Center has provided state-of-the-art cancer care for more than 20 years, and is the only cancer center in Kentucky designated by the National Cancer Institute. In August 2017, Markey was named as one of the Top 50 Cancer Centers in the nation by U.S. News & World Report. The clinical programs and services of the UK Markey Cancer Center are integrated with the UK Albert B. Chandler Hospital. Markey's cancer specialty teams work together with UK Hospital departments and divisions to provide primary patient care and support services as well as advanced specialty care with applicable clinical trials. Patients seen at Markey have access to more than 100 nationally sponsored clinical studies for different types of cancer. Markey researchers and clinicians are dedicated to taking new cancer treatments from the laboratory to patients and improving the health of all Kentuckians.
The Indiana University Melvin and Bren Simon Cancer Center is one of the leading academic cancer research centers in the United States. It is Indiana’s only National Cancer Institute (NCI)-designated cancer center that provides patient care and is one of only 70 in the nation. The NCI designation recognizes that our collaborative research programs meet the NCI’s rigorous criteria for world-class, state-of-the-art programs in multidisciplinary cancer research that reaches all 92 counties in Indiana. It also means that the scientific discoveries made by researchers at the IU Simon Cancer Center benefit patients close to home throughout the state. Our researchers have made protocol-defining discoveries that have changed the way doctors treat testicular cancer, breast cancer, gastrointestinal cancer, genitourinary cancer, leukemia, multiple myeloma, thymoma and thymic carcinomas, and thoracic cancer. Our researchers and physicians are dedicated to eliminating cancer’s burden in Indiana and beyond.
10902 N. McKinley Drive
Tampa, FL 33612
F (813) 384-5049